

FOR IMMEDIATE RELEASE



October 16, 2014

AnGes MG, Inc.

First Patient Dosed in Physician-led Study of HGF Gene Therapy in Japan

AnGes MG, Inc. ("AnGes") announced today that the first patient in the physician-led clinical study*¹ was dosed with AnGes's HGF gene therapy (DNA Plasmid with HGF Gene)*² for Critical Limb Ischemia (CLI).

The clinical study is led by Osaka University Hospital and conducted at several study sites under the Advanced Medical Treatment System (B group). AnGes will provide the test drug as well as data accumulated through past development.

*1 This clinical study targets patients with chronic arterial occlusive disease (arteriosclerotic obliteration and Burger's disease) in which alternate treatments are not applicable.

*2 Beperminogene perplasmid, "Collategene."

*3 The Advanced Medical Treatment System in Japan allows for a combination of services covered by public health insurance and advanced medical technology (not covered by public health insurance) if safety and efficacy are assured. The Advanced Medical Treatment System includes groups A and B, in which group B applies to treatments utilizing unapproved or off-label (unapproved usage of) drugs or medical devices.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGes MG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 http://www.anges-mg.com</p>
